A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women

Overview

Journal Int J Endocrinol

Publisher Wiley

Specialty Endocrinology

Date 2016 Aug 6

PMID 27493664

Citations 28

Authors

Elena Benelli

Scilla Del Ghianda

Caterina Di Cosmo

Massimo Tonacchera

Affiliations

Soon will be listed here.

Abstract

Introduction. We evaluated the effects of a therapy that combines myo-inositol (MI) and D-chiro-inositol (DCI) in young overweight women affected by polycystic ovary syndrome (PCOS), characterized by oligo- or anovulation and hyperandrogenism, correlated to insulin resistance. Methods. We enrolled 46 patients affected by PCOS and, randomly, we assigned them to two groups, A and B, treated, respectively, with the association of MI plus DCI, in a 40 : 1 ratio, or with placebo (folic acid) for six months. Thus, we analyzed pretreatment and posttreatment FSH, LH, 17-beta-Estradiol, Sex Hormone Binding Globulin, androstenedione, free testosterone, dehydroepiandrosterone sulphate, HOMA index, and fasting glucose and insulin. Results. We recorded a statistically significant reduction of LH, free testosterone, fasting insulin, and HOMA index only in the group treated with the combined therapy of MI plus DCI; in the same patients, we observed a statistically significant increase of 17-beta-Estradiol levels. Conclusions. The combined therapy of MI plus DCI is effective in improving endocrine and metabolic parameters in young obese PCOS affected women.

Citing Articles

Myo-Inositol and Its Derivatives: Their Roles in the Challenges of Infertility.

Placidi M, Casoli G, Tatone C, Emidio G, Bevilacqua A Biology (Basel). 2024; 13(11).

PMID: 39596891 PMC: 11592302. DOI: 10.3390/biology13110936.

[Polycystic ovary syndrome: new and promising treatment methods].

Gasieva D, Sheremetyeva E, Kalashnikova M, Dzgoeva F, Alborova E Probl Endokrinol (Mosk). 2024; 70(4):103-113.

PMID: 39302870 PMC: 11551798. DOI: 10.14341/probl13400.

Treatment With a Patented 3.6:1 Myo-Inositol to D-chiro-Inositol Ratio, Antioxidants, Vitamins and Minerals Food Supplement in Women With a History of Assisted Reproductive Technique (ART) Failures: A Series of Case Reports.

Armijo-Sanchez A, Benitez Castillo N, Garcia-Vidal E, Luna Chadid M, Salvador Ballada C, Valls Ricart G Clin Med Insights Case Rep. 2024; 17:11795476241242265.

PMID: 38559382 PMC: 10981332. DOI: 10.1177/11795476241242265.

Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines.

Fitz V, Graca S, Mahalingaiah S, Liu J, Lai L, Butt A J Clin Endocrinol Metab. 2024; 109(6):1630-1655.

PMID: 38163998 PMC: 11099481. DOI: 10.1210/clinem/dgad762.

Combined Inositols, α-Lactalbumin, Gymnema Sylvestre and Zinc Improve the Lipid Metabolic Profile of Patients with Type 2 Diabetes Mellitus: A Randomized Clinical Trial.

Nani A, Bertuzzi F, Meneghini E, Mion E, Pintaudi B J Clin Med. 2023; 12(24).

PMID: 38137721 PMC: 10743679. DOI: 10.3390/jcm12247650.

References

Unfer V, Carlomagno G, Papaleo E, Vailati S, Candiani M, Baillargeon J . Hyperinsulinemia Alters Myoinositol to d-chiroinositol Ratio in the Follicular Fluid of Patients With PCOS. Reprod Sci. 2014; 21(7):854-858. DOI: 10.1177/1933719113518985. View

Stepto N, Cassar S, Joham A, Hutchison S, Harrison C, Goldstein R . Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod. 2013; 28(3):777-84. DOI: 10.1093/humrep/des463. View

Minozzi M, Nordio M, Pajalich R . The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. Eur Rev Med Pharmacol Sci. 2013; 17(4):537-40. View

Bevilacqua A, Carlomagno G, Gerli S, Oliva M, Devroey P, Lanzone A . Results from the International Consensus Conference on myo-inositol and D-chiro-inositol in Obstetrics and Gynecology--assisted reproduction technology. Gynecol Endocrinol. 2015; 31(6):441-6. DOI: 10.3109/09513590.2015.1006616. View

Facchinetti F, Bizzarri M, Benvenga S, DAnna R, Lanzone A, Soulage C . Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS. Eur J Obstet Gynecol Reprod Biol. 2015; 195:72-76. DOI: 10.1016/j.ejogrb.2015.09.024. View

Pasquali R, Pelusi C, Ragazzini C, Hasanaj R, Gambineri A . Glucose tolerance, insulin secretion and insulin sensitivity in polycystic ovary syndrome. JOP. 2002; 3(1):1-7. View

Dunaif A . Insulin resistance in women with polycystic ovary syndrome. Fertil Steril. 2006; 86 Suppl 1:S13-4. DOI: 10.1016/j.fertnstert.2006.04.011. View

Cinar N, Harmanci A, Bayraktar M, Yildiz B . Ethinyl estradiol-drospirenone vs ethinyl estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2012; 78(3):379-84. DOI: 10.1111/j.1365-2265.2012.04415.x. View

. ACOG Practice Bulletin No. 108: Polycystic ovary syndrome. Obstet Gynecol. 2009; 114(4):936. DOI: 10.1097/AOG.0b013e3181bd12cb. View

10.

Marshall J, Dunaif A . Should all women with PCOS be treated for insulin resistance?. Fertil Steril. 2011; 97(1):18-22. PMC: 3277302. DOI: 10.1016/j.fertnstert.2011.11.036. View

11.

Nestler J, Stovall D, Akhter N, Iuorno M, Jakubowicz D . Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril. 2002; 77(2):209-15. DOI: 10.1016/s0015-0282(01)02963-6. View

12.

Lagana A, Barbaro L, Pizzo A . Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol. Arch Gynecol Obstet. 2014; 291(5):1181-6. DOI: 10.1007/s00404-014-3552-6. View

13.

Dunaif A . Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997; 18(6):774-800. DOI: 10.1210/edrv.18.6.0318. View

14.

Larner J . D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res. 2002; 3(1):47-60. PMC: 2478565. DOI: 10.1080/15604280212528. View

15.

Alvarez-Blasco F, Botella-Carretero J, San Millan J, Escobar-Morreale H . Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med. 2006; 166(19):2081-6. DOI: 10.1001/archinte.166.19.2081. View

16.

Nestler J, Strauss 3rd J . Insulin as an effector of human ovarian and adrenal steroid metabolism. Endocrinol Metab Clin North Am. 1991; 20(4):807-23. View

17.

Sun T, Heimark D, Nguygen T, Nadler J, Larner J . Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem Biophys Res Commun. 2002; 293(3):1092-8. DOI: 10.1016/S0006-291X(02)00313-3. View

18.

Heimark D, McAllister J, Larner J . Decreased myo-inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. Endocr J. 2013; 61(2):111-7. DOI: 10.1507/endocrj.ej13-0423. View

19.

Unfer V, Carlomagno G, Dante G, Facchinetti F . Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012; 28(7):509-15. DOI: 10.3109/09513590.2011.650660. View

20.

De Leo V, Musacchio M, Morgante G, Piomboni P, Petraglia F . Metformin treatment is effective in obese teenage girls with PCOS. Hum Reprod. 2006; 21(9):2252-6. DOI: 10.1093/humrep/del185. View